Leaving GSK Pro

You are leaving GSK Pro to visit a separate website not associated with GSK Pro, a portal for US Healthcare Professionals.There are website links to third-party sites on GSK Pro. GSK is not responsible for content on third-party websites.

Continue

Cancel

Rely on GSK to provide a flu vaccine that offers the same dose (0.5-mL) for a broad age range of patients, aged 6 months and older.1,2

3 ways to order or prebook

Call 1-855-475-4QIV (4748)

Online at GSKDirect.com 

Contact your GSK Vaccines Sales Representative

Presentation

FLULAVAL QUADRIVALENT is available in1,3

0.5-mL single-dose prefilled syringes (package of 10)

  • Thimerosal free
  • Disposable
  • Packaged without needles
  • CPT code 90686

References:

  1. Prescribing Information for FLULAVAL QUADRIVALENT.
  2. Grohskopf LA, Sokolow LZ, Broder KR, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices - United States, 2018-19 influenza season. MMWR. 2018;67(3):1-20. https://www.cdc.gov/mmwr/volumes/67/rr/pdfs/rr6703a1-H.pdf. Published August 24, 2018. Accessed November 14, 2018.
  3. American Medical Association. CPT® 2019 Professional Edition. Chicago, IL: AMA Press; 2018.
  4. Prescribing Information for Fluzone Quadrivalent.
  5. Hibbs BF, Moro PL, Lewis P, et al. Vaccination errors reported to the Vaccine Adverse Event Reporting System, (VAERS) United States, 2000-2013. Vaccine. 2015;33(28):3171-3178.
  6. Institute for Safe Medication Practices. Frequently reported vaccine errors to ISMP VERP. Pharm Today. 2016;22(1):72.
  7. Influenza: about flu. Centers for Disease Control and Prevention website. https://www.cdc.gov/flu/about/index.html. Updated October 26, 2018. Accessed November 14, 2018.
  8. Estimated Influenza Illnesses, Medical Visits, and Hospitalizations Averted by Vaccination in the United States. Centers for Disease Control and Prevention website. https://www.cdc.gov/flu/about/disease/2016-17.htm. Updated May 22, 2016. Accessed November 14, 2018.
  9. Flu vaccination coverage, United States, 2016-17 influenza season. Centers for Disease Control and Prevention website. https://www.cdc.gov/flu/fluvaxview/coverage-1617estimates.htm. Updated September 28, 2017. Accessed November 14, 2018.
  10. People 65 years and older & influenza. Centers for Disease Control and Prevention website. https://www.cdc.gov/flu/about/disease/65over.htm. Updated September 4, 2018. Accessed November 14, 2018.
  11. People at high risk of developing serious flu-related complications. Centers for Disease Control and Prevention website. https://www.cdc.gov/flu/about/disease/high_risk.htm. Updated August 27, 2018. Accessed November 14, 2018.

INDICATION

FLULAVAL QUADRIVALENT is a vaccine indicated for active immunization for the prevention of disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. FLULAVAL QUADRIVALENT is approved for use in persons aged 6 months and older.

Important Safety Information for FLULAVAL QUADRIVALENT

  • Do not administer FLULAVAL QUADRIVALENT to anyone with a history of severe allergic reactions (eg, anaphylaxis) to any component of the vaccine, including egg protein, or following a previous dose of any influenza vaccine
  • If Guillain-Barré syndrome has occurred within 6 weeks of receipt of a prior influenza vaccine, the decision to give FLULAVAL QUADRIVALENT should be based on careful consideration of the potential benefits and risks
  • Syncope (fainting) can occur in association with administration of injectable vaccines, including FLULAVAL QUADRIVALENT. Procedures should be in place to avoid falling injury and to restore cerebral perfusion following syncope
  • If FLULAVAL QUADRIVALENT is administered to immunosuppressed persons, including individuals receiving immunosuppressive therapy, the immune response may be lower than in immunocompetent persons
  • In clinical trials with FLULAVAL QUADRIVALENT in adults, the most common solicited local adverse reaction was pain and the most common solicited systemic adverse reactions were muscle aches, headache, fatigue, and arthralgia. In children 6 through 35 months of age, the most common solicited local adverse reaction was pain and the most common solicited systemic adverse reactions were irritability, drowsiness, and loss of appetite. In children 3 through 17 years of age, the most common solicited local adverse reaction was pain. In children 3 through 4 years of age, the most common solicited systemic adverse reactions were irritability, drowsiness, and loss of appetite. In children 5 through 17 years of age, the most common solicited systemic adverse reactions were muscle aches, fatigue, headache, arthralgia, and gastrointestinal symptoms. (See Adverse Reactions section of the Prescribing Information for FLULAVAL QUADRIVALENT for other potential adverse reactions and events)
  • Vaccination with FLULAVAL QUADRIVALENT may not result in protection in all vaccine recipients

Please see full Prescribing Information for FLULAVAL QUADRIVALENT.

All trademarks are the property of their respective owners.